fashion -WSS

fashion

author：knowledge 2025-09-06 04:50:54 - browse：475

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Medicare bonuses could stop drug shortages under Senate plan

hotspot

WSS

Dog Aging Project founders on what lies ahead after losing funding

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Why more medical students aren't specializing in primary care

How a symptom of dementia informs our understanding of creativity

Feds fine Medicare Advantage plans for overcharging members

There's an unseen cost to disruptive road

Wikipedia

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The high cost of giving birth even with insurance

In science, is the line between industry and academia shifting?

Duchenne breakthrough therapy leaves behind pioneering families

Flu vaccine reformulation won't be easy, manufacturers warn

Medicare details structure of new drug price negotiation program

A pediatrician calls for Congress to pass the child tax credit deal

New air purifier tech could be key to improving indoor air quality

Neuroscience startup Neumora files for IPO

Guidelines to prevent youth baseball injuries need more muscle

What causes osteoarthritis? Researchers study link to brain protein

hotspot

Dog Aging Project founders on what lies ahead after losing funding

Cardiologists urge adding sexual orientation, gender identity to health records

How a symptom of dementia informs our understanding of creativity

HPV vaccine, cervical cancer study delivers historic results

Appeals court upholds limits to abortion pill

Complete sequence of Y chromosome published for first time

explore

hotspot

Wikipedia

leisure time